MBRX · ISSUER CIK 1659617
Moleculin Biotech, Inc.
Between Jul 31, 2026 and Oct 28, 2026, 3 Moleculin Biotech, Inc. insiders reported $0.00 of open-market purchases and $0.00 of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. No open-market sales in the window.
$0.00Insider buying
$0.00Insider selling
$0.00Net open-market
Oct 16, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 202621:00 | Oct 15, 2026 | MBRX | CEO and President, Director | M · Exercise | — | +207,500 | 771,840 | +37% | — | ||
| Oct 16, 202621:00 | Oct 15, 2026 | MBRX | CEO and President, Director | F · Tax | $0.37 | −48,659 | 723,181 | -6% | $18K | ||
| Oct 16, 202621:00 | Oct 15, 2026 | MBRX | Chief Financial Officer | M · Exercise | — | +130,000 | 435,673 | +43% | — | ||
| Oct 16, 202621:00 | Oct 15, 2026 | MBRX | Chief Financial Officer | F · Tax | $0.37 | −30,485 | 405,188 | -7% | $11K | ||
| Aug 5, 202616:16 | Aug 3, 2026 | MBRX | Chief Financial Officer | P · Buy | — | +293,333 | 305,673 | +2377% | — | — | — |
| Aug 5, 202616:16 | Aug 3, 2026 | MBRX | CEO and President, Director | P · Buy | — | +533,333 | 564,340 | +1720% | — | — | — |
| Aug 5, 202616:15 | Aug 3, 2026 | MBRX | Chief Science Officer | P · Buy | — | +173,333 | 174,086 | +23019% | — | — | — |